Biomaterials Firm Bolt Threads, Formerly A Unicorn, Plans SPAC Deal At A $250 Million Valuation
CEO Dan Widmaier talks exclusively with Forbes about going public and the ups and downs of running a synthetic biology firm.
Stay updated with breaking news from David Breslauer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CEO Dan Widmaier talks exclusively with Forbes about going public and the ups and downs of running a synthetic biology firm.
Houston Public Media's Hurricane Season recalls the Category 3 storm which made landfall this week in 1983.
Boosting the production of Mylo mycelium
/PRNewswire/ -- Bolt Threads, a biotechnology company creating the next generation of advanced materials, and Ginkgo Bioworks (NYSE: DNA), the leading...
One of the hottest new ideas in fashion comes from mycelium, the fibers that form the basis of mushrooms – a plant-based option that its makers say is durable, without the environmental or cruelty concerns that can come with animal skins.